Neha Mehta-Shah, MD, MSCI is an Assistant Professor of Medicine at Washington University in St. Louis where she specializes in T-cell lymphomas.  She completed her undergraduate and medical school at Northwestern University and then completed residency at New York Presbyterian-Weill Cornell Medical Center. She was selected as chief resident at Memorial Sloan Kettering where she completed fellowship in 2016.   She then completed a Masters of Science in Clinical Investigation at Washington University in St. Louis. She has been recognized with young investigator awards from ASH, the Lymphoma Research Foundation, the T-cell Leukemia Lymphoma Society,  the Alliance and a Paul Calabresi K12 Award. She leads multiple trials in T-cell lymphoma locally and nationally.

C. Ola Landgren, M.D., Ph.D., Conference Chair

Dr. C. Ola Landgren, Professor of Medicine, Chief of Myeloma Program, Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami (SCCC-UM).

Over the past several years, he designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease (monoclonal gammopathy of undetermined significance [MGUS] and smoldering myeloma) to multiple myeloma. Beyond traditional clinical criteria for complete remission, he developed strategies to define minimal residual disease (MRD) detection post-therapy in multiple myeloma using cell-, molecular-, and imaging-based methods. He has a strong track-record in drug development and served as a principal investigator for many clinical trials, with particular focus on early drug development and correlative science.

He leads the clinical and research operations along with the development of the Myeloma Program at SCCC-UM. He is a frequent speaker and faculty member for national and international meetings on myeloma and hematologic malignancies. He is a member of several editorial boards and serves as a reviewer for grants and several high-impact journals. As a Program Member of the Cancer Center Support Grant, he participates in research activities as an independent investigator, a leader of research governance committees, and on multi-disciplinary research teams.